NASUS PHARMA LTD
NSRXNYSE AMERICAN๐ #4446 by market capUS Equity
โโ
Quote unavailableTrack NSRX
Get earnings, price moves & breaking news on Telegram
24hโ
7dโ
14dโ
30dโ
ytdโ
1yโ
๐ฆMarket Cap
$27M
Small Cap
๐Revenue Growth (YoY)
โ
๐Gross Margin
โ
๐ตFCF Margin
โ
โ๏ธP/S Ratio
โ
Otter Score
โ
Insufficient data
No chart data available for NSRX.
Trading Snapshot
- Day Range
- โ
- 52-Week Range
- $1.98 โ $9.50
- Volume (shares)
- โ
- Avg Volume (shares)
- โ
- Shares Outstanding
- 11.7M
- Next Earnings
- โ
Fundamentals Snapshot
- Annual Revenue
- โ
- Last Q Revenue
- โ
- P/E Ratio
- โ
- P/S Ratio
- โ
- EPS (TTM)
- $-0.87
- Dividend Yield
- โ
NASUS PHARMA LTD
NSRXFinancial Trends
Financial history unavailable.
About NASUS PHARMA LTD
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
๐ฆฆ
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Overall Score
Insufficient data
โ/100
Analyst data unavailable.
Latest News & Updates
News unavailable.